| Followers | 71 |
| Posts | 8989 |
| Boards Moderated | 0 |
| Alias Born | 03/06/2016 |
Friday, October 05, 2018 10:51:40 AM
“I know what I know and you nor any other questionable long won't change it”
I’m not looking to change any minds. I’m just perplexed why do many give TGD so many “get out of jail cards” without providing an honest update or explain why his conservative timelines were too optimistic?
If you know what you know then why would you have thrown so much money here for many years in advanced? Serious question. By your way of thinking, it may make sense to wait 9 months to invest. Yeah, sure you may miss the run from $2.40 to $24.00 but you saved yourself a lot of angst and were still able to enjoy the ride from $24 to $1,000.
Based on what I have experienced over the last 6 years or so, I don’t believe Rett will start this calendar year. I took a lot of flack last January when we were all disappointed Rett didn’t start last year. In January I said it probably won’t start until Q3 and most thought that it was a ludicrous statement. I removed the rose colored glasses in January and I suspect many will remove them this coming January if Rett doesn’t start by then.
What was Fadiran hired to do? His expertise is the FDA and not Australia nor the EMA so why no trial starting her? Don’t blame PM. My reason why Rett won’t start anytime soon is because the “cabal” game needs to be played out longer and if Rett were to start soon the anticipated early results would be expected in 3 months or so and that is way too soon for the “cabal”. The “cabal” is greedy and wants more stock grants and options before any trial results. The lastest form4 is evidence.
I’m not looking to change any minds. I’m just perplexed why do many give TGD so many “get out of jail cards” without providing an honest update or explain why his conservative timelines were too optimistic?
If you know what you know then why would you have thrown so much money here for many years in advanced? Serious question. By your way of thinking, it may make sense to wait 9 months to invest. Yeah, sure you may miss the run from $2.40 to $24.00 but you saved yourself a lot of angst and were still able to enjoy the ride from $24 to $1,000.
Based on what I have experienced over the last 6 years or so, I don’t believe Rett will start this calendar year. I took a lot of flack last January when we were all disappointed Rett didn’t start last year. In January I said it probably won’t start until Q3 and most thought that it was a ludicrous statement. I removed the rose colored glasses in January and I suspect many will remove them this coming January if Rett doesn’t start by then.
What was Fadiran hired to do? His expertise is the FDA and not Australia nor the EMA so why no trial starting her? Don’t blame PM. My reason why Rett won’t start anytime soon is because the “cabal” game needs to be played out longer and if Rett were to start soon the anticipated early results would be expected in 3 months or so and that is way too soon for the “cabal”. The “cabal” is greedy and wants more stock grants and options before any trial results. The lastest form4 is evidence.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
